Literature DB >> 10903246

Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice.

S I Hagiwara1, Y Ishii, S Kitamura.   

Abstract

Reactive oxygen species (ROS) play an important role in the pathogenesis of pulmonary fibrosis. We previously demonstrated that N-acetylcysteine (NAC), an antioxidant, inhibited adhesion molecule expression and cytokine production in lung cells. When NAC is inhaled into the alveolar space, it is expected to directly interact with inflammatory cells and to elevate glutathione levels in the epithelial lining fluids. We therefore examined whether inhaled NAC inhibits lung fibrosis induced by bleomycin (BLM). Male ICR mice were given a single intravenous injection of BLM (150 mg/ kg). Thirty milliliters of NAC (70 mg/ml) or saline were inhaled twice a day for 28 d using an ultrasonic nebulizer. In the inflammatory phase (Day 7), NAC administration attenuated the cellular infiltration in both bronchoalveolar lavage fluid (BALF) and alveolar tissues. At Day 28, the fibrotic changes estimated by Aschroft's criteria and hydroxyproline content in the NAC inhalation group were significantly decreased compared with the BLM-only group (p < 0.05). CXC chemokines, macrophage inflammatory protein-2 (MIP-2), cytokine-induced neutrophil chemoattractant (KC), and CC chemokines, macrophage inflammatory protein-1alpha (MIP-1alpha), in BALF were mostly elevated on Day 7 in the BLM-only group; however, these elevations were significantly repressed by NAC inhalation (p < 0.05). Lipid hydroperoxide (LPO) was also quantified in BALF. LPO was markedly increased on Day 3 in the BLM-only group, and this increase was significantly decreased by NAC inhalation (p < 0.05). These results revealed that aerosolized NAC ameliorated acute pulmonary inflammation induced by BLM injection via the repression of chemokines and LPO production, resulting in the attenuation of subsequent lung fibrosis. These findings are limited to the BLM-induced lung fibrosis animal model. However, NAC inhalation will be expected to be a potential therapy for patients with other interstitial pneumonias because ROS are involved in the pathogenesis of lung injury in most interstitial pneumonia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903246     DOI: 10.1164/ajrccm.162.1.9903129

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  69 in total

1.  Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-L-cysteine, and novel thiol antioxidant, N,N'-bis-2-mercaptoethyl isophthalamide.

Authors:  Rishi B Patel; Sainath R Kotha; Lynn A Sauers; Smitha Malireddy; Travis O Gurney; Niladri N Gupta; Terry S Elton; Ulysses J Magalang; Clay B Marsh; Boyd E Haley; Narasimham L Parinandi
Journal:  Toxicol Mech Methods       Date:  2012-06       Impact factor: 2.987

Review 2.  N-acetylcysteine -- passe-partout or much ado about nothing?

Authors:  Mirja-Liisa Aitio
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

3.  Effects of erdosteine on bleomycin-induced lung fibrosis in rats.

Authors:  Haşim Boyaci; Hale Maral; Gupse Turan; Ilknur Başyiğit; Meltem O Dillioğlugil; Füsun Yildiz; Melih Tugay; Ayşe Pala; Cengiz Erçin
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

4.  Metabolomic study on bleomycin and polyhexamethylene guanidine phosphate-induced pulmonary fibrosis mice models.

Authors:  Chan Seo; Sung-Hwan Kim; Hyeon-Seong Lee; Moongi Ji; Jeuk Min; Young-Jin Son; In-Hyeon Kim; Kyuhong Lee; Man-Jeong Paik
Journal:  Metabolomics       Date:  2019-08-17       Impact factor: 4.290

5.  N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis.

Authors:  January N Baumgardner; Kartik Shankar; Leah Hennings; Emanuele Albano; Thomas M Badger; Martin J J Ronis
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

6.  NRF2 deficiency reduces life span of mice administered thoracic irradiation.

Authors:  Elizabeth L Travis; Girish Rachakonda; Xinhui Zhou; Katrina Korhonen; Konjeti R Sekhar; Swati Biswas; Michael L Freeman
Journal:  Free Radic Biol Med       Date:  2011-06-12       Impact factor: 7.376

7.  In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats.

Authors:  A Serrano-Mollar; D Closa; N Prats; S Blesa; M Martinez-Losa; J Cortijo; J M Estrela; E J Morcillo; O Bulbena
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 8.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

9.  Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disorders corrected with treatment of baicalin in a murine model.

Authors:  Changfeng Hu; Yiqi Wang; Yongsheng Fan; Haichang Li; Chunyan Wang; Jida Zhang; Shuijuan Zhang; Xianlin Han; Chengping Wen
Journal:  AAPS J       Date:  2015-03-12       Impact factor: 4.009

Review 10.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.